| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 1,160 | 970 | 390 | 820 | 1,960 |
| Sales Growth | +19.59% | +148.72% | -52.44% | -58.16% | +402.56% |
| Net Income | -1,980 | -1,790 | -2,010 | -1,550 | -200 |
| Net Income Growth | -10.61% | +10.95% | -29.68% | -675.00% | +90.24% |
Dyadic International (DYAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms including humans found in the earth's biodiversity. Using its integrated technology platform, Dyadic develops biological products such as proteins, enzymes, polypeptides and small molecules for applications in large segments of the agricultural, industrial, chemical and biopharmaceutical industries. By utilizing a proprietary host organism, Dyadic's `one-stop shop` technology rapidly discovers and expresses eukaryotic genes the genes of complex living organisms and then manufactures those unique biological products for commercial application. Dyadic's systems overcome the inadequacy of existing gene discovery and product development techniques.
Fiscal Year End Date: 12/31